Sciele and Addrenex submit NDA for hypertension drug
Upon approval from the FDA, Addrenex and its licensing partner Sciele Pharma, will launch the drug in the first half of 2009. Patrick Fourteau, CEO of Sciele, said:
miRecule has signed a research collaboration with EM subsidiary Rio Biofarma Brasil (RBBL) to co-develop peptide-mediated delivery technologies aimed at improving targeted ribonucleic acid (RNA) therapeutics delivery to tissues beyond the liver and muscles in a range of disease areas.